Raymond James raised the firm’s price target on Alnylam (ALNY) to $424 from $370 and keeps an Outperform rating on the shares. Alnylam reported a strong Q2 beat and guidance raise on a very encouraging first full quarter of commercial launch for Amvuttra, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $449 from $304 at Piper Sandler
- Alnylam price target raised to $550 from $403 at UBS
- Alnylam price target raised to $415 from $390 at Canaccord
- Alnylam Pharma: Strong Financials and Strategic Advancements Drive Buy Rating
- Alnylam price target raised to $405 from $312 at Morgan Stanley